Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Sakigake Status Awarded to GSK’s Next-Gen I/O Therapy, 2 More Drugs; System Possibly Subject to Review Next Time
June 22, 2020
- MHLW Council Determines High Medical Needs for 2 Antiemetics
June 22, 2020
- MHLW Delays Chuikyo Discussion Timeline for Off-Year Price Survey, Drops June-End Goal
June 22, 2020
- LDP Pharma Study Group Submits Proposal, Says Off-Year Re-Pricing Should Be Delayed
June 19, 2020
- First Generics for 18 APIs Join NHI Price List; Patent Row-Hit Edirol Gx, 7 AGs Included
June 19, 2020
- Chuikyo Doctor Reps Nix Drug Price Survey Discussion, Say It Should Only Come after Govt’s Go/No-Go Decision
June 18, 2020
- MHLW Plans to Introduce Scheme to Scrutinize Generic Makers’ Stable Supply Ability, Beginning with December Listing
June 18, 2020
- Orphan Status for Otsuka’s Sakigake-Designated Product, and 4 Other Cell and Gene Therapies Endorsed
June 18, 2020
- 0.1% of Tokyo Residents Test Positive for Coronavirus Antibodies: MHLW
June 17, 2020
- Label Revisions Ordered for Avastin, Memary
June 17, 2020
- Japan Stiffens Foreign Investment Rules for Certain Drug, Medical Device Manufacturers
June 16, 2020
- MHLW to Propose Two-Third Sampling Rate for Wholesaler Survey for Off-Year Drug Re-Pricing; Go/No-Go Debate to Continue
June 16, 2020
- MHLW Starts Inviting Coronavirus Vaccine Developers after 2nd Extra Budget Passed
June 15, 2020
- MHLW to Allow Blood Collection for Use of Blood in Drug R&D under Amended Blood Law
June 12, 2020
- Industry Says There’s No Way Off-Year Drug Price Survey Can Be Done; Chuikyo Healthcare Reps Agree but Payers Don’t
June 11, 2020
- LDP Study Group Calls for Postponing Off-Year Re-Pricing
June 9, 2020
- Stable Supply Debate Set to Heat Up in Japan, Scientific Societies to Select Key Drugs by June-End
June 9, 2020
- JPMA Urges Govt to Establish “Headquarters” for Infectious Disease Control Policy: Chief
June 9, 2020
- MHLW Grants Orphan Status to 8 APIs
June 8, 2020
- Minister Mentions First Half 2021 Goal for Coronavirus Vaccination Start
June 8, 2020
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…